Literature DB >> 1583146

Niacin-positive Mycobacterium kansasii isolated from immunocompromised patients.

I Nachamkin1, R R MacGregor, J L Staneck, A Y Tsang, J C Denner, M Willner, S Barbagallo.   

Abstract

Niacin-positive Mycobacterium kansasii was isolated from three patients, two with respiratory infections and one with a perirectal abscess. The isolates were phenotypically similar to other strains of M. kansasii, differing only in their ability to produce niacin. This phenotype has been reported only twice in the literature, during the 1960s.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1583146      PMCID： PMC265283          DOI： 10.1128/jcm.30.5.1344-1346.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Mycobacterium kansasii infection limited to skin and lymph node in a patient with AIDS.

Authors:  H J Stellbrink; K Koperski; H Albrecht; H Greten
Journal:  Clin Exp Dermatol       Date:  1990-11       Impact factor: 3.470

2.  Trehalose-containing lipooligosaccharides from mycobacteria: structures of the oligosaccharide segments and recognition of a unique N-acylkanosamine-containing epitope.

Authors:  S W Hunter; I Jardine; D L Yanagihara; P J Brennan
Journal:  Biochemistry       Date:  1985-05-21       Impact factor: 3.162

3.  Disseminated infection with Mycobacterium kansasii in the acquired immunodeficiency syndrome.

Authors:  R Sherer; R Sable; M Sonnenberg; S Cooper; P Spencer; S Schwimmer; F Kocka; P Muthuswamy; C Kallick
Journal:  Ann Intern Med       Date:  1986-11       Impact factor: 25.391

Review 4.  Nontuberculous mycobacteria and associated diseases.

Authors:  E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1979-01

5.  Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection.

Authors:  B Levine; R E Chaisson
Journal:  Ann Intern Med       Date:  1991-05-15       Impact factor: 25.391

6.  Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare.

Authors:  C H Ahn; J W McLarty; S S Ahn; S I Ahn; G A Hurst
Journal:  Am Rev Respir Dis       Date:  1982-04

7.  Cutaneous lesions due to Mycobacterium kansasii.

Authors:  R Bolivar; T K Satterwhite; M Floyd
Journal:  Arch Dermatol       Date:  1980-02

8.  Pulmonary infection caused by niacin-positive Mycobacterium kansasii. A case report with autopsy findings.

Authors:  W Y Yue; S S Cohen
Journal:  Am Rev Respir Dis       Date:  1966-09

9.  Comprehensive approach to identification of serovars of Mycobacterium avium complex.

Authors:  J C Denner; A Y Tsang; D Chatterjee; P J Brennan
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

Review 10.  Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects.

Authors:  G L Woods; J A Washington
Journal:  Rev Infect Dis       Date:  1987 Mar-Apr
View more
  3 in total

1.  Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.

Authors:  Moti Chapagain; Tawanda Gumbo; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.

Authors:  Sanjay Singh; Tawanda Gumbo; Gunavanthi D Boorgula; Prem Shankar; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2022-08-17       Impact factor: 5.938

3.  Tentative evidence of AIDS-associated biotype of Mycobacterium kansasii.

Authors:  E Tortoli; M T Simonetti; C Lacchini; V Penati; P Urbano
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.